Advances in Experimental and Translational Research in the Treatment of Hepatocellular Carcinoma

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 377-389

  Kidner, Travis ^a   Dai, Menghua ^a   Adusumilli, Prasad S ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOSINE DEAMINASE; DOXORUBICIN; EDMONTON VACCINE STRAIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; INTERLEUKIN 8; MICROSPHERE; NITRIC OXIDE; ONYX 015; PLATELET DERIVED GROWTH FACTOR; PRODRUG; PROTEIN TYROSINE KINASE; PURINE NUCLEOSIDE PHOSPHORYLASE; SCATTER FACTOR; SOMATOMEDIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VACCINE; VASCULOTROPIN; YTTRIUM 90;

ADENOVIRUS; ANGIOGENESIS; BIOLOGICAL THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CHEMOEMBOLIZATION; CRYOABLATION; DRUG DELIVERY SYSTEM; ELECTROSURGERY; ENZYME PHOSPHORYLATION; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOTHERAPY; INCIDENCE; LIVER CELL CARCINOMA; MEASLES VIRUS; MICROWAVE COAGULATION THERAPY; MICROWAVE THERAPY; ONCOLYTIC VIROTHERAPY; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; REVIEW; TUMOR SUPPRESSOR GENE; VESICULAR STOMATITIS VIRUS;

BIOLOGICAL THERAPY; CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; GENE THERAPY; HUMANS; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; RISK FACTORS;

EID: 41049105819     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.01.002     Document Type: Review

References (60)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics. CA Cancer J Clin 55 (2005) 74-108
2. Thomas M.B., and Zhu A.X. Hepatocellular carcinoma: the need for progress. J Clin Oncol 23 (2005) 2892-2899
3. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
5. Hussain S.A., Ferry D.R., El-Gazzaz G., et al. Hepatocellular carcinoma. Ann Oncol 12 (2001) 161-172
6. Bosch F.X., Ribes J., Cleries R., et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9 (2005) 191-211
7. Morgan T.R., Mandayam S., and Jamal M.M. Alcohol and hepatocellular carcinoma. Gastroenterology 127 Suppl (2004) S87-S96
8. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
9. Kulik L.M. Advancements in hepatocellular carcinoma. Curr Opin Gastroenterol 23 (2007) 268-274
10. Fong Y., Sun R.L., Janagin W., et al. An analysis of 412 cases of hepatocellular carcinoma at a Western Center. Ann Surg 229 (1999) 790-799
11. Poon R.T., Fan S.T., Lo C.M., et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234 (2001) 63-70
12. Iwatsuki S., Starzl T.E., Sheahan D.R., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 214 (1991) 221-228
13. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
14. Arciero C.A., and Sigurdson E.R. Liver-directed therapies for hepatocellular carcinoma. J Natl Compr Canc Netw 4 8 (2006) 768-774
15. Colleoni M., Audisoio R.A., De Braud F., et al. Practical considerations in the treatment of hepatocellular carcinoma. Drugs 55 (1998) 367-382
16. Gates V.L., Atassi B., Lewandowski R.J., et al. Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. Future Oncol 3 1 (2007) 73-81
17. Chan E.S., Chow P.K., Tai B., et al. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2 (2000) CD001199
18. Blaese R.M., Culver K.W., Miller A.D., et al. T-lymphocyte-directed gene therapy for ADA-SCID: intial trial results after 4 years. Science 270 (1995) 475-480
19. Guan Y.S., La Z., Yang L., et al. p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol 13 7 (2007) 985-992
20. Iwasaki Y., Ueda M., Yamada T., et al. Gene therapy of liver tumors with human liver specific nanoparticles. Cancer Gene Ther 14 (2007) 74-81
21. Gao D.C., An W., and Dai J. Retrovirus-mediated herpes simplex virus thymidine kinase gene therapy approach for hepatocellular carcinoma. Cell Res 9 (1999) 225-235
22. Tsuchiyama T., Kaneko S., Nakamoto Y., et al. Enhanced antitumor effects of bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther 10 (2003) 260-269
23. Gerolami R., Uch R., Faivre J., et al. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1 derived lentiviral vectors. J Hepatol 40 (2004) 291-297
24. Hwang L.H. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci 13 (2006) 453-468
25. Hernandez-Alcoceba R., Sangro B., and Prieto J. Gene therapy of liver cancer. World J Gastroenterol 12 38 (2006) 6085-6097
26. Mitry R.R., Sarraf C.E., Havlik R., et al. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology 31 (2000) 885-889
27. Xu G.W., Sun Z.T., Forrester K., et al. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 24 (1996) 1264-1268
28. Hollstein M., Sidransky D., Vogelstein B., et al. p53 mutations in human cancers. Science 253 (1991) 49-53
29. Blackburn E.H. Telomeres and telomerase. Keio J Med 49 (2000) 59-65
30. Dean N.M., and Bennett C.F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 23 (2003) 9087-9096
31. Trojan L.A., Kopinski P., Wei M.X., et al. IGF-I: from diagnostic to triple helix gene therapy of solid tumors. Acta Biochim Pol 49 (2002) 979-990
32. Yazaki T., Manz H.J., Rabkin S.D., et al. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55 21 (1995) 4752-4756
33. Bischoff J.R., Kirn I., Williams A., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
34. Kemeny N., Brown K., Covey A., et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17 (2006) 1214-1224
35. Blechacz B., Splinter P.L., Greiner S., et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44 6 (2006) 1465-1477
36. Peng K.W., Ahmann G.J., Pham L., et al. Systemic therapy for myeloma xenografts by an attenuated measles virus. Blood 98 (2001) 2002-2007
37. Phuong L.K., Allen C., Peng K.W., et al. Use of vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63 (2003) 2462-2469
38. Grote D., Russell S.J., Cornu T.I., et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97 (2001) 3746-3754
39. Chung Y.S., Atake S.I., Miyamoto A., et al. Oncolytic recombinate herpes simplex virus for treatment of orthotopic liver tumors in nude mice. Int J Oncol 28 (2006) 793-798
40. Bennett J.J., Kooby D.A., Delman K., et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 78 (2000) 166-174
41. Mineta T., Rabkin S.D., Yazaki T., et al. Attenuated multi-mutated herpes simples virus-1 for the treatment of malignant gliomas. Nat Med 1 (1995) 938-943
42. Song T.J., Einsenberg D.P., Adusumilli P.S., et al. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. J Gastrointest Surg 10 4 (2006) 532-542
43. Iankov I.D., Blechacz B., Liu C., et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15 1 (2007) 114-122
44. Shinozaki K., Ebert O., Suriawinata A., et al. Prophylatic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. Journal of Virology 79 21 (2005) 13705-13713
45. Takahashi M., Sato T., Sagawa T., et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 5 (2002) 627-634
46. Sagawa T., Takahashi M., Sato T., et al. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter. Mol Ther 10 (2004) 1043-1050
47. Hawkins M.A., and Dawson L.A. Radiation therapy for hepatocellular carcinoma. Cancer 106 8 (2006) 1653-1663
48. Gulec S.A., Mesoloras G., Dezarn W.A., et al. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 5 (2007) 15
49. Carr B.I. Hepatic arterial 90-Yttrium glass microspheres (therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10 (2004) S107-S110
50. Roberts L.R., and Gores G.J. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerging Drugs 11 3 (2006) 469-487
51. Avila M.A., Berasain C., and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25 (2006) 3866-3884
52. Gish R.G. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol 4 3 (2006) 252-261
53. Hasegawa K., Takayama T., Lijchi M., et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 44 (2006) 891-895
54. Epstein R.J., and Leung T.W. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 13 1 (2007) 11-17
55. Thomas M.B., and Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23 31 (2005) 8093-8108
56. Eskens F.A. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br J Cancer 90 (2004) 1-7
57. Ryan A.J., and Wedge S.R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 Suppl 1 (2005) S6-S13
58. Liu Y., Poon R.T., Li Q., et al. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65 (2005) 3691-3699
59. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23 27 (2005) 6657-6663
60. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 26 (2006) 4293-4300